Expression of smooth muscle cell-specific proteins in neural progenitor cells induced by agonists of G protein-coupled receptors and transforming growth factor-beta.
Neural progenitor cells isolated from the embryonic cerebral cortex are well known to differentiate into neurons and glial cells, but recent reports have demonstrated differentiation into smooth muscle cells (SMCs) under the influence of fetal bovine serum. In this study, we report that agonists for G protein-coupled receptors (GPCRs), including endothelin, lysophosphatidic acid and carbachol, effectively promote the expression of SMC-specific proteins in the presence of transforming growth factor-beta (TGF-beta). Incubation of neural progenitor cells with agonists for GPCRs or TGF-beta alone induced the expression of an SMC-specific protein, alpha-smooth muscle actin (SMA), and their combination resulted in incremental increase. Stimulation with combinations of each GPCR agonist and TGF-beta increased the numbers of large, flat cells with thick actin fibers and also caused expression of other SMC marker proteins. Endothelin and TGF-beta enhanced SMA promoter-luciferase reporter activity at different times after stimulation. The mutation of TGF-beta control element of SMA promoter constructs decreased TGF-beta-enhanced luciferase activity but not endothelin-stimulated activity. Transfection of active forms of RhoA and its effector, mDia, strongly enhanced SMA promoter activity, and a dominant negative form of RhoA inhibited endothelin-stimulated promoter activity but not TGF-beta-stimulated activity. Whereas endothelin consistently activated RhoA, TGF-beta did not, and a specific inhibitor of TGF-beta type I receptor blocked TGF-beta-enhanced SMA promoter activity, suggesting involvement of Smad phosphorylation. These results suggest that separate signaling pathways of G protein and TGF-beta cooperatively promote the expression of SMC-specific proteins in neural progenitor cells.
Morishita
Rika
R
Department of Molecular Neurobiology, Institute for Developmental Research, Aichi Human Service Center, Kasugai, Aichi, Japan.
Nagata
Koh-Ichi
K
Ito
Hidenori
H
Ueda
Hiroshi
H
Asano
Masahisa
M
Shinohara
Haruo
H
Kato
Kanefusa
K
Asano
Tomiko
T
D000199:Actins / Q000378:metabolism*; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004622:Embryo, Mammalian; D016232:Endothelins / Q000494:pharmacology; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects*; D008246:Lysophospholipids / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects*; D016548:Prosencephalon / Q000166:cytology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D043562:Receptors, G-Protein-Coupled / Q000819:agonists* / Q000037:antagonists & inhibitors; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013234:Stem Cells / Q000187:drug effects*; D013997:Time Factors; D014162:Transfection / Q000379:methods; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D000199:Actins; D002217:Carbachol; D016232:Endothelins; D008246:Lysophospholipids; D012333:RNA, Messenger; D043562:Receptors, G-Protein-Coupled; D016212:Transforming Growth Factor beta; C498862:Acta2 protein, rat; C032881:lysophosphatidic acid